In several studies, KRAS mutations in patients with colorectal cancer are associated with resistance to therapy with anti-EGFR antibodies and it is the only biomarker for predicting patient outcome when treated with targeted anti-HER therapies in colorectal cancer [29]. Here, KRAS is linked to colorectal cancer.